Magnolia Bark Extract - NutraPedia

Back to Table of Contents

Magnolia Bark Extract

1) Conditions Studied

Magnolia bark extract has been studied for various conditions including:

  • Anxiety and stress-related disorders
  • Depression
  • Insomnia and sleep disturbances
  • Weight management and obesity
  • Dental issues, such as bad breath and gingivitis
  • Inflammation and pain
  • Alzheimer's disease and other cognitive impairments

2) Efficacy in Treating Conditions

While some studies suggest that magnolia bark extract may help with anxiety, insomnia, and cognitive function, the evidence is not conclusive. Further research is needed to determine its efficacy in treating these conditions consistently.

3) Health Benefits

The potential health benefits of magnolia bark extract include:

  • Reduction of anxiety and stress
  • Improvement in sleep quality
  • Anti-inflammatory effects
  • Antibacterial properties, particularly in oral health
  • Antioxidant effects
  • May support weight loss
  • Potential cognitive enhancement

4) Downsides

Magnolia bark extract may have some downsides, such as:

  • Possible side effects including heartburn, shaking hands, thyroid problems, sexual problems, and headaches
  • Interactions with medications, especially those that are changed by the liver
  • Safety concerns for pregnant or breastfeeding women due to lack of research
  • Potential drowsiness, which could affect tasks that require alertness

5) Impact on Specific Genetic Variations

There is limited research on the interaction between magnolia bark extract and specific genetic variations. However, individuals with certain genetic profiles may experience different effects or metabolize the compounds in magnolia bark differently. It's important to consult with a healthcare provider before using magnolia bark extract, especially if there are known genetic concerns.

Summary of Magnolia Bark Extract Research

Magnolia bark extract, particularly the compound honokiol, plays a crucial role in the anxiolytic and antidepressant effects of traditional Chinese and Japanese Kampo medicines. Research has demonstrated that honokiol is responsible for the anxiety-reducing properties of Hange-koboku-to and Saiboku-to, as its removal from these medicines resulted in the loss of anxiolytic effects. Honokiol has also shown antidepressant-like effects in rodents, countering depression-related biochemical changes.

Further studies have isolated and purified honokiol and magnolol from Magnolia officinalis, confirming their high purity and potential for further investigation into their interaction with depression-related biological systems. The compounds have been subjected to various methods for assessing quality, with magnolol and honokiol being critical for differentiating between samples of Magnoliae officinalis Cortex.

In addition to mental health, honokiol and magnolol have been studied for their effects on cancer, inflammation, and oxidative stress. Honokiol, for instance, can cross the blood-brain barrier and inhibit the growth of brain tumors, offering a promising new therapy for gliosarcoma. It has also been found to enhance GABA(A) receptor activity, contributing to its anxiolytic and central depressant effects.

Overall, the extract from Magnolia bark and its compounds, honokiol and magnolol, possess a range of pharmacological effects, making them subjects of interest for the potential treatment of various conditions, including anxiety, depression, and cancer.

References:


  1. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark
  2. Asthma as well as anxiety improved by the Kampo extract Saiboku-to
  3. Antidepressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula
  4. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents
  5. Isolation and purification of honokiol and magnolol from cortex Magnoliae officinalis by high-speed counter-current chromatography
  6. Quality assessment of commercial Magnoliae officinalis Cortex by ¹H-NMR-based metabolomics and HPLC methods
  7. A comparative study of upright counter-current chromatography and high-performance liquid chromatograpohy for preparative isolation and purification ofphenolic compounds from Magnoliae officinalis
  8. [Effects of primary processing on quality of cortex Magnolia officinalis]
  9. Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx
  10. Studies on the alkaloids of the bark of Magnolia officinalis: isolation and on-line analysis by HPLC-ESI-MS(n)
  11. Effects of constituents from the bark of Magnolia obovata on nitric oxide production in lipopolysaccharide-activated macrophages
  12. Metabolites of orally administered Magnolia officinalis extract in rats and man and its antidepressant-like effects in mice
  13. Phenolic glycosides and other constituents from the bark of Magnolia officinalis
  14. [Variation of phenolic compound contents of Magnolia officinalis at different levels]
  15. [Phenols in seedling cortex of Magnolia officinalis from Enshi]
  16. Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol
  17. Therapeutic applications of compounds in the Magnolia family
  18. [Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and hõnokiol in M. obovata and other allied plants]
  19. Comparative studies on the interactions of honokiol and magnolol with human serum albumin
  20. Systematic analysis of post-administrative saiboku-to urine by liquid chromatography to determine pharmacokinetics of traditional Chinese medicine
  21. Disposition of magnolol after intravenous bolus and infusion in rabbits
  22. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection
  23. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model
  24. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites
  25. Effects of honokiol and magnolol on acetylcholine release from rat hippocampal slices
  26. Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats
  27. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity
  28. Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice
  29. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors
  30. Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship
  31. Magnolol enhances pentobarbital-induced sleeping behaviors: possible involvement of GABAergic systems
  32. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice
  33. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABA(A) receptor in mice
  34. Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures
  35. Effects of extract and ingredients isolated from Magnolia obovata thunberg on catecholamine secretion from bovine adrenal chromaffin cells
  36. Interactions of Magnolia and Ziziphus extracts with selected central nervous system receptors
  37. Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism
  38. Magnolol decreases body temperature by reducing 5-hydroxytryptamine release in the rat hypothalamus
  39. Modulatory effects of magnolol on potassium-stimulated 5-hydroxytryptamine release from rat cortical and hippocampal slices
  40. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice
  41. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects
  42. The clinical presentation of generalized anxiety in primary-care settings: practical concepts of classification and management
  43. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial
  44. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause
  45. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause
  46. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial
  47. Antidepressant-like effect of magnolol on BDNF up-regulation and serotonergic system activity in unpredictable chronic mild stress treated rats
  48. Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats
  49. Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats
  50. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development
  51. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance
  52. PPARs and the complex journey to obesity
  53. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist
  54. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema
  55. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo
  56. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma
  57. Honokiol: a non-adipogenic PPARγ agonist from nature
  58. Honokiol enhances adipocyte differentiation by potentiating insulin signaling in 3T3-L1 preadipocytes
  59. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene
  60. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells
  61. Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice
  62. Prevalence of periodontitis in adults in the United States: 2009 and 2010
  63. Host-parasite interactions in periodontitis: subgingival infection and host sensing
  64. Aggregatibacter actinomycetemcomitans as indicator for aggressive periodontitis by two analysing strategies
  65. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis
  66. Magnolol ameliorates ligature-induced periodontitis in rats and osteoclastogenesis: in vivo and in vitro study
  67. Antimicrobial activity of magnolol and honokiol against periodontopathic microorganisms
  68. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis
  69. Magnolol stimulates lipolysis in lipid-laden RAW 264.7 macrophages
  70. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production
  71. Protective effects of honokiol and magnolol on tertiary butyl hydroperoxide- or D-galactosamine-induced toxicity in rat primary hepatocytes
  72. Honokiol, a multifunctional antiangiogenic and antitumor agent
  73. Comparison of antioxidant abilities of magnolol and honokiol to scavenge radicals and to protect DNA
  74. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo
  75. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway
  76. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
  77. Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo
  78. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
  79. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells
  80. Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis
  81. Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth
  82. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO
  83. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
  84. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction
  85. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells
  86. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma
  87. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol
  88. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model
  89. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore
  90. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells
  91. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells
  92. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells
  93. Behavioral and biochemical studies on chronic mild stress models in rats treated with a Chinese traditional prescription Banxia-houpu decoction
  94. Orthogonal array design for antidepressant compatibility of polysaccharides from Banxia-Houpu decoction, a traditional Chinese herb prescription in the mouse models of depression


Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!